Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287945 · ClinicalTrials.gov registry record · Phase 1
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
A Phase 1 study of Carcinoma, Renal Cell, sponsored by Oncorena AB.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT05287945 is a Phase 1 study of Carcinoma, Renal Cell that is actively recruiting participants, run by Oncorena AB. The registered enrollment target is 75 participants, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05287945, a Phase 1 study of Carcinoma, Renal Cell, is actively recruiting participants, sponsored by Oncorena AB.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma.
Conditions Studied
Interventions
- DRUG Orellanine
Study Locations (3)
Missouri
- Washington University in St. Louis - St Louis
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Other
- Karolinska University Hospital - Stockholm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-08-04 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05287945
The ClinicalTrials.gov registry entry for NCT05287945 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (73% lower). The listed sponsor is Oncorena AB, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Orellanine is the first listed.
NCT05287945 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Missouri, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT05287945 about?
NCT05287945 is a clinical study titled "Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma". A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma.
What is the current status of trial NCT05287945?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2023-08-04. Estimated completion is 2027-12-31.
What conditions does trial NCT05287945 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT05287945?
The interventions under investigation include: Orellanine (DRUG).
Who is sponsoring clinical trial NCT05287945?
This trial is sponsored by Oncorena AB, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05287945 being conducted?
This trial has 3 study locations across Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.